{
    "clinical_study": {
        "@rank": "50222", 
        "arm_group": [
            {
                "arm_group_label": "CABG+ Botulinum toxin", 
                "arm_group_type": "Active Comparator", 
                "description": "All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Active Comparator", 
                "description": "All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this prospective randomized double-blind study was to compare the efficacy and\n      safety of Botulinum toxin injection in epicardial fat pads for preventing recurrences (in\n      early postoperative period) of atrial tachyarrhythmia in patients with paroxysmal atrial\n      fibrillation undergoing coronary artery bypass graft (CABG) surgery."
        }, 
        "brief_title": "Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Paroxysmal Atrial Fibrillation", 
            "Indications for CABG"
        ], 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  PAF\n\n          -  Indication for CABG according to the American College of Cardiology/American Heart\n             Association (ACC/AHA) guidelines for CABG surgery\n\n        Exclusion Criteria:\n\n          -  Previous heart surgery and AF ablation procedure\n\n          -  Emergency CABG\n\n          -  Unstable angina or heart failure\n\n          -  Persistent AF, AF at the time of screening (planned Maze procedure or pulmonary vein\n             isolation)\n\n          -  Use of I or III antiarrhythmic drugs within 5 elimination half-lives of the drug (or\n             within 2 months for amiodarone)\n\n          -  Requiring concomitant valve surgery\n\n          -  Left ventricle ejection fraction <35%\n\n          -  Left atrial diameter >55 mm\n\n          -  Unwillingness to participate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842529", 
            "org_study_id": "BT13-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "CABG+ Botulinum toxin", 
                "intervention_name": "botulinum toxin injection", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control", 
                "intervention_name": "0.9% normal saline injection", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "CABG+ Botulinum toxin", 
                    "Control"
                ], 
                "intervention_name": "Implantable loop recorder", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Botulinum Toxins"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 30, 2014", 
        "link": {
            "description": "State Research Institute of Circulation Pathology Official Site", 
            "url": "http://meshalkin.ru"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "The Valley Health System and Columbia University College of Physicians & Surgeons"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novosibirsk", 
                        "country": "Russian Federation", 
                        "zip": "630055"
                    }, 
                    "name": "State Research Institute of Circulation Pathology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tomsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Institute of Cardiology, Siberian Division of Russian Academy of Medical Sciences"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Botulinum Toxin Injection in Epicardial Fat Pads Can Prevent Recurrences of Atrial Fibrillation After Cardiac Surgery: Randomized Pilot Study", 
        "overall_official": {
            "affiliation": "State Research Institute of Circulation Pathology", 
            "last_name": "Evgeny Pokushalov, MD, PhD, FESC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "recurrence of > 30 secs of atrial tachyarrhythmia, including AF and atrial flutter/tachycardia, after CABG procedure on no antiarrhythmic drug", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842529"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "time intervals from end of surgery to weaning from ventilation, extubation and discharge from ICU", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "post-CABG length of stay", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "incidence of congestive heart failure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "incidence of sustained  ventricular arrhythmias", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "incidence of myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "incidence of renal failure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "incidence of respiratory failure", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "stroke or transient ischemic attack", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "rehospitalization", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "readmission to ICU", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "number of deaths", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "post-CABG length of stay", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Meshalkin Research Institute of Pathology of Circulation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meshalkin Research Institute of Pathology of Circulation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}